Anatara Lifesciences Ltd (
Anatara made two notable announcements during the quarter; reporting the achievement of key milestones for its GaRP dietary supplement development program: (1) additional successful preclinical data, including observing an adjuvant effect and potential dose-sparing properties when combined with a commonly used class of disease modifying medication; (2) finalisation of the draft clinical trial protocol in irritable bowel syndrome (IBS).
To view the release, please visit:
https://abnnewswire.net/lnk/VTV619SM
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
Contact
Investor and Media inquiriesSteven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com
Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com
Related Companies
Related Industry Topics: